SCHOTT Pharma KGaA Full Year 2024 Earnings: EPS Beats Expectations

editorial-team@simplywallst.com (Simply Wall St)

Tue, Dec 17, 2024, 6:02 AM 1 min read

SCHOTT Pharma KGaA (ETR:1SXP) Full Year 2024 Results

Key Financial Results

Revenue: €957.1m (up 6.5% from FY 2023).
Net income: €149.7m (down 1.4% from FY 2023).
Profit margin: 16% (down from 17% in FY 2023). The decrease in margin was driven by higher expenses.
EPS: €0.99 (down from €1.01 in FY 2023).

revenue-and-expenses-breakdown — XTRA:1SXP Revenue and Expenses Breakdown December 17th 2024

All figures shown in the chart above are for the trailing 12 month (TTM) period

SCHOTT Pharma KGaA EPS Beats Expectations

Revenue was in line with analyst estimates. Earnings per share (EPS) surpassed analyst estimates by 2.1%.

The primary driver behind last 12 months revenue was the Drug Containment Solutions (DCS) segment contributing a total revenue of €518.7m (54% of total revenue). Notably, cost of sales worth €634.5m amounted to 66% of total revenue thereby underscoring the impact on earnings. The largest operating expense was Sales & Marketing costs, amounting to €79.8m (46% of total expenses). Explore how 1SXP's revenue and expenses shape its earnings.

Looking ahead, revenue is forecast to grow 11% p.a. on average during the next 3 years, compared to a 11% growth forecast for the Life Sciences industry in Europe.

Performance of the market in Germany.

The company's shares are down 11% from a week ago.

Balance Sheet Analysis

While earnings are important, another area to consider is the balance sheet. See our latest analysis on SCHOTT Pharma KGaA's balance sheet health.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.